正在研发的用于应对甲型H1N1流感感染的抗病毒化合物。
ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.
作者信息
Beigel J H
机构信息
Science Applications International in support of the Laboratory of Immunoregulation, Division of Intramural Research, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
出版信息
Drugs Future. 2010 May;35(5):385-392. doi: 10.1358/dof.2010.035.05.1487081.
Abstract
The recent pandemic of H1N1 has demonstrated the potential vulnerability of the human population to novel influenza viruses. While there is recent increased interest and effort in developing effective anti-influenza agents, few new products have entered clinical studies. This review will highlight the limited armamentarium of licensed influenza agents, and discuss novel compounds and strategies that have entered clinical studies and may therefore be imminently available to the treating clinician.
摘要
近期甲型H1N1流感大流行已表明人类群体对新型流感病毒存在潜在的易感性。尽管最近在开发有效的抗流感药物方面兴趣和努力有所增加，但进入临床研究的新产品却很少。本综述将着重介绍已获许可的流感药物的有限种类，并讨论已进入临床研究、因此治疗临床医生可能很快就能使用的新型化合物和策略。
相似文献
1
ANTIVIRAL COMPOUNDS IN THE PIPELINE TO TACKLE H1N1 INFLUENZA INFECTION.正在研发的用于应对甲型H1N1流感感染的抗病毒化合物。
Drugs Future. 2010 May;35(5):385-392. doi: 10.1358/dof.2010.035.05.1487081.
2
Natural Product-Derived Phytochemicals for Influenza A Virus (H1N1) Prevention and Treatment.天然产物衍生的植物化学物质防治甲型流感病毒 (H1N1)。
Molecules. 2024 May 17;29(10):2371. doi: 10.3390/molecules29102371.
3
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.新型甲型 H1N1 流感病毒被神经氨酸酶融合蛋白 DAS181 强力抑制。
PLoS One. 2009 Nov 6;4(11):e7788. doi: 10.1371/journal.pone.0007788.
4
Discovery of oseltamivir-based novel PROTACs as degraders targeting neuraminidase to combat H1N1 influenza virus.发现基于奥司他韦的新型PROTACs作为靶向神经氨酸酶的降解剂以对抗H1N1流感病毒。
Cell Insight. 2022 May 12;1(3):100030. doi: 10.1016/j.cellin.2022.100030. eCollection 2022 Jun.
5
Identification and Characterization of Novel Compounds with Broad-Spectrum Antiviral Activity against Influenza A and B Viruses.具有抗甲型和乙型流感病毒广谱抗病毒活性的新型化合物的鉴定与表征
J Virol. 2020 Mar 17;94(7). doi: 10.1128/JVI.02149-19.
6
Pandemic H1N1 2009 influenza A virus induces weak cytokine responses in human macrophages and dendritic cells and is highly sensitive to the antiviral actions of interferons.2009 年甲型 H1N1 流感大流行病毒在人类巨噬细胞和树突状细胞中诱导较弱的细胞因子反应，并且高度敏感于干扰素的抗病毒作用。
J Virol. 2010 Feb;84(3):1414-22. doi: 10.1128/JVI.01619-09. Epub 2009 Nov 25.
7
Influenza A(H1N1)pdm09 virus suppresses RIG-I initiated innate antiviral responses in the human lung.甲型 H1N1pdm09 病毒抑制人肺中 RIG-I 引发的先天抗病毒反应。
PLoS One. 2012;7(11):e49856. doi: 10.1371/journal.pone.0049856. Epub 2012 Nov 21.
8
Treatment of severe cases of pandemic (H1N1) 2009 influenza: review of antivirals and adjuvant therapy.2009年甲型H1N1流感大流行重症病例的治疗：抗病毒药物及辅助治疗综述
Recent Pat Antiinfect Drug Discov. 2010 Jun;5(2):152-6. doi: 10.2174/157489110791233513.
9
Pandemic H1N1 influenza A viruses are resistant to the antiviral activities of innate immune proteins of the collectin and pentraxin superfamilies.甲型H1N1大流行性流感病毒对凝集素和五聚素超家族固有免疫蛋白的抗病毒活性具有抗性。
J Immunol. 2010 Oct 1;185(7):4284-91. doi: 10.4049/jimmunol.1001613. Epub 2010 Sep 3.
10
Research paths to successful prevention and treatment of swine-derived H1N1 influenza virus infection.
Drug News Perspect. 2010 Jan-Feb;23(1):65-70. doi: 10.1358/dnp.2010.23.1.1416985.
引用本文的文献
1
#Nitrosocarbonyls 1: antiviral activity of N-(4-hydroxycyclohex-2-en-1-yl)quinoline-2-carboxamide against the influenza A virus H1N1.# 亚硝基羰基化合物1：N-(4-羟基环己-2-烯-1-基)喹啉-2-甲酰胺对甲型H1N1流感病毒的抗病毒活性
ScientificWorldJournal. 2014;2014:472373. doi: 10.1155/2014/472373. Epub 2014 Dec 31.
2
siRNA Genome Screening Approaches to Therapeutic Drug Repositioning.siRNA 基因组筛选方法在治疗药物重定位中的应用。
Pharmaceuticals (Basel). 2013 Jan 28;6(2):124-60. doi: 10.3390/ph6020124.
3
Model-based simulation and prediction of an antiviral strategy against influenza A infection.基于模型的模拟和预测抗甲型流感病毒感染的抗病毒策略。
PLoS One. 2013 Jul 9;8(7):e68235. doi: 10.1371/journal.pone.0068235. Print 2013.
4
Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.以丙磺舒为新型抗甲型流感病毒策略靶向有机阴离子转运蛋白 3。
Antimicrob Agents Chemother. 2013 Jan;57(1):475-83. doi: 10.1128/AAC.01532-12. Epub 2012 Nov 5.
本文引用的文献
1
Rapid selection of oseltamivir- and peramivir-resistant pandemic H1N1 virus during therapy in 2 immunocompromised hosts.免疫功能低下宿主治疗过程中对奥司他韦和帕拉米韦耐药的大流行 H1N1 病毒的快速选择。
Clin Infect Dis. 2010 May 1;50(9):1252-5. doi: 10.1086/651605.
2
Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro.金刚烷胺、利巴韦林和奥司他韦三联用药对体外耐药流感病毒株具有高度活性和协同作用。
PLoS One. 2010 Feb 22;5(2):e9332. doi: 10.1371/journal.pone.0009332.
3
Sialidase-based anti-influenza virus therapy protects against secondary pneumococcal infection.基于唾液酸酶的抗流感病毒疗法可预防二次肺炎链球菌感染。
J Infect Dis. 2010 Apr 1;201(7):1007-15. doi: 10.1086/651170.
4
Hark back: passive immunotherapy for influenza and other serious infections.追溯：流感和其他严重感染的被动免疫疗法。
Crit Care Med. 2010 Apr;38(4 Suppl):e66-73. doi: 10.1097/CCM.0b013e3181d44c1e.
5
Clinical pharmacokinetics of laninamivir, a novel long-acting neuraminidase inhibitor, after single and multiple inhaled doses of its prodrug, CS-8958, in healthy male volunteers.在健康男性志愿者中，单次和多次吸入其前药 CS-8958 后新型长效神经氨酸酶抑制剂拉尼米韦的临床药代动力学。
J Clin Pharmacol. 2010 Nov;50(11):1319-29. doi: 10.1177/0091270009356297. Epub 2010 Feb 9.
6
Influenza antiviral therapeutics.流感抗病毒治疗药物。
Recent Pat Antiinfect Drug Discov. 2010 Jan;5(1):64-75. doi: 10.2174/157489110790112527.
7
Effects of the combination of favipiravir (T-705) and oseltamivir on influenza A virus infections in mice.法匹拉韦（T-705）与奥司他韦联合用药对小鼠流感病毒感染的影响。
Antimicrob Agents Chemother. 2010 Jan;54(1):126-33. doi: 10.1128/AAC.00933-09. Epub 2009 Nov 9.
8
Inhibition of neuraminidase inhibitor-resistant influenza virus by DAS181, a novel sialidase fusion protein.新型唾液酸酶融合蛋白 DAS181 抑制神经氨酸酶抑制剂耐药性流感病毒。
PLoS One. 2009 Nov 6;4(11):e7838. doi: 10.1371/journal.pone.0007838.
9
Novel pandemic influenza A(H1N1) viruses are potently inhibited by DAS181, a sialidase fusion protein.新型甲型 H1N1 流感病毒被神经氨酸酶融合蛋白 DAS181 强力抑制。
PLoS One. 2009 Nov 6;4(11):e7788. doi: 10.1371/journal.pone.0007788.
10
The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza.帕拉米韦用于治疗2009年甲型H1N1流感的紧急使用授权。
N Engl J Med. 2009 Dec 3;361(23):2204-7. doi: 10.1056/NEJMp0910479. Epub 2009 Nov 2.
Zotero 插件